Early detection of bone marrow engraftment by amplification of hypervariable DNA regions
- PMID: 9175318
Early detection of bone marrow engraftment by amplification of hypervariable DNA regions
Abstract
Background and objective: After allogeneic bone marrow transplantation (BMT) it is important to be able to distinguish between the host and donor origin of cells in order to monitor the engraftment process. However, identifying whether the hematopoietic stem cells are of donor or recipient origin may be a difficult task. DNA studies using Southern blotting techniques or the amplification by PCR of regions in the human genome with high polymorphic neutral sequence variation showing Mendelian inheritance as variable number of tandem repeats (VNTR) can detect the origin of host bone marrow after BMT. We have tried to apply these sensitive systems of detection to the early stages of BMT when small numbers of regenerated cells are available for analysis.
Methods: We used in vitro polymerase chain reaction (PCR) amplification of three single-locus simple repetitive DNA sequences, all of which vary extensively in their repeat number among different individuals (VNTR D1S80, ApoB, and D17S5), to evaluate post transplant engraftment in six patients who showed no signs of peripheral blood engraftment at 2-3 weeks after transplant. We tested 2 patients with chronic myelogenous leukemia (CML), 2 with B-acute lymphoblastic leukemia (B-ALL), 1 with T-acute lymphoblastic leukemia (T-ALL), and 1 with aplastic anemia (SAA), all in prolonged aplasia following allogeneic bone marrow transplantation (BMT).
Results: In a sequential analysis protocol with the different loci, the donor was distinguishable from the recipient in all pairs with at least one of the three markers used. After 16 days (median 16.2; range 15 to 20 days) we found that complete chimerism was present in 5 patients: 4 of donor origin (= engraftment) and one of host origin (= rejection), this last case being one of mixed chimerism. In the 2 cases in which the presence (one complete and one partial) of host DNA was detected, rejection of the donor bone marrow followed, and in 1 patient a second BMT was necessary. The other 4 patients with complete chimerism of donor origin achieved hematological reconstitution and we documented complete engraftment of donor bone marrow a few months later.
Interpretation and conclusions: Utilizing PCR to document early post-transplant engraftment and chimerism in the first month after BMT has the advantage over Southern blotting of being more sensitive and requiring small amounts of sample. It may also be useful for guiding subsequent therapeutic decisions.
Similar articles
-
In vitro amplification of hypervariable DNA regions for the evaluation of chimerism after allogeneic BMT.Bone Marrow Transplant. 1993 Aug;12(2):115-20. Bone Marrow Transplant. 1993. PMID: 8401355
-
[Application of sequential and quantitative monitoring of chimerism in allogeneic hematopoietic stem cell transplantation].Zhonghua Xue Ye Xue Za Zhi. 2004 Feb;25(2):78-81. Zhonghua Xue Ye Xue Za Zhi. 2004. PMID: 14990044 Chinese.
-
Detection of chimerism and early engraftment after allogeneic peripheral blood stem cell or bone marrow transplantation by short tandem repeats.Am J Hematol. 1996 Aug;52(4):281-7. doi: 10.1002/(SICI)1096-8652(199608)52:4<281::AID-AJH7>3.0.CO;2-O. Am J Hematol. 1996. PMID: 8701946
-
Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation.Biol Blood Marrow Transplant. 2001;7(9):473-85. doi: 10.1053/bbmt.2001.v7.pm11669214. Biol Blood Marrow Transplant. 2001. PMID: 11669214 Review.
-
Use of DNA polymorphisms to monitor engraftment after allogeneic bone marrow transplantation.Clin Lab Med. 1997 Mar;17(1):109-18. Clin Lab Med. 1997. PMID: 9138894 Review.
Cited by
-
Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide as an Effective Regimen for Prophylaxis of Graft Versus Host Disease After Haploidentical Peripheral Blood Stem Cell Transplantation With Maternal/Collateral Related Donors.Cell Transplant. 2022 Jan-Dec;31:9636897221139103. doi: 10.1177/09636897221139103. Cell Transplant. 2022. PMID: 36433646 Free PMC article.
-
Prevalence of chimerism after non-myeloablative hematopoietic stem cell transplantation.Sao Paulo Med J. 2009 Sep;127(5):251-8. doi: 10.1590/s1516-31802009000500002. Sao Paulo Med J. 2009. PMID: 20169272 Free PMC article.
-
Lower Absolute Lymphocyte Count Before Conditioning Predicts High Relapse Risk in Patients After Haploidentical Peripheral Blood Stem Cell Transplantation With Low Dose Anti-Thymocyte Globulin/Post-Transplant Cyclophosphamide for GvHD Prophylaxis.Cell Transplant. 2022 Jan-Dec;31:9636897221079739. doi: 10.1177/09636897221079739. Cell Transplant. 2022. PMID: 35225024 Free PMC article.
-
Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study.Bone Marrow Transplant. 2019 Jul;54(7):1049-1057. doi: 10.1038/s41409-018-0382-3. Epub 2018 Nov 16. Bone Marrow Transplant. 2019. PMID: 30446741 Free PMC article. Clinical Trial.
-
Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML.Bone Marrow Transplant. 2016 Dec;51(12):1561-1564. doi: 10.1038/bmt.2016.217. Epub 2016 Aug 15. Bone Marrow Transplant. 2016. PMID: 27526282
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous